AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AMGEN INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$424.94−7.55 (-1.75%)
Close on Oct 19, 2026
- Market cap
- $231.17B
- P/E (TTM)
- 26.4
- Dividend yield
- 2.27%
Share price
+$126.13 (+42.21%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
AMGEN INC grew revenue 9.1% to $38.10B over the twelve months to Jun 30, 2026. Operating income rose 39.5% to $11.43B, moving the operating margin from 23.5% to 30.0%. Free cash flow was $10.18B, down 4.1% from a year earlier.
Revenue
$38.10B
+9.1% vs. a year earlier
Operating income
$11.43B
+39.5% vs. a year earlier
Free cash flow
$10.18B
-4.1% vs. a year earlier
EPS, diluted
$16.10
+31.6% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $231.17B
- P/E ratio
- 26.4
- Price to sales
- 6.07
- Price to book
- 19.78
- Dividend yield
- 2.27%
- Free cash flow yield
- 4.40%
Fundamentals
- Revenue
- $38.10B
- Net income
- $8.74B
- EPS, diluted
- $16.10
- Free cash flow
- $10.18B
- Book value per share
- $21.49
- Diluted shares
- 544M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$38.10B+9.1% YoY
Gross profit
$26.48B+17.6% YoY
Operating income
$11.43B+39.5% YoY
Net income
$8.74B+32.1% YoY
EPS, diluted
$16.10+31.6% YoY
Free cash flow
$10.18B-4.1% YoY
Reported periodTrailing twelve months